Teijin licenses febuxostat to Astellas in Taiwan

Teijin Pharma has licensed TMX-67 (febuxostat), a drug for treating hyperuricemia in patients with gout, to the Taiwanese sales  and marketing arm of fellow Japanese drugmaker Astellas, which will  manage the approval process and handle sales of TMX-67 after its  commercial launch, which is targeted at 2013. Teijin will supply the  finished product and receive an upfront licensing fee, as well as  commercial milestone payments. Further financial terms were not  disclosed.